{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:30:14Z","timestamp":1786437014305,"version":"build-2736575974"},"reference-count":63,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5,16]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Chimeric antigen receptor T cell (CAR-T) therapy is an innovation in oncology, which provides targeted treatment alternatives for certain tumors. CAR-T therapy has been associated to adverse cardiovascular consequences despite its potential for therapeutic benefit. As research in this field expands rapidly, a bibliometric study is needed to map the current state of knowledge and highlight emerging areas of interest to guide future studies and optimize patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A comprehensive bibliometric analysis was conducted using the Web of Science Core Collection and PubMed to examine the literature on CAR-T cell therapy and its cardiovascular implications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The annual number of publications on CAR-T therapy and cardiovascular symptoms has steadily increased, experiencing a significant surge starting in 2018. The USA, China, and Germany emerged as the leading contributors. Key journals included Frontiers in Immunology and Blood, while highly cited journals were Lancet Oncology and the Journal of Clinical Oncology. Keyword analysis identified multiple myeloma, immunotherapy, and cytokine release syndrome as major research themes. The clustered map highlighted interconnected research areas, with a significant focus on multiple myeloma, combination therapy, cardiovascular magnetic resonance assessment, and novel therapeutic approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This bibliometric analysis provided a detailed overview of the research landscape on CAR-T cell therapy and its cardiovascular implications, identifying trends and gaps in knowledge. Recent research trends highlighted bispecific antibodies, CAR-T cell therapy, cardiovascular events, lymphoma, management, and outcomes as emerging focus areas. These keywords underscore the developing field of cardiac events, management, and outcomes in patients undergoing CAR-T cell therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000042314","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T14:01:42Z","timestamp":1747836102000},"page":"e42314","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Research trends in CAR-T cell therapy: A comprehensive bibliometric analysis highlighting cardiovascular toxicity and clinical implications"],"prefix":"10.1097","volume":"104","author":[{"given":"Daniyal","family":"Ameen","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Yale New Haven Health Bridgeport Hospital, Bridgeport, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4985-2899","authenticated-orcid":false,"given":"Ehsan","family":"Amini-Salehi","sequence":"additional","affiliation":[{"name":"School of Medicine, Guilan University of Medical Science, Rasht, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep Samethadka","family":"Nayak","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yale New Haven Health Bridgeport Hospital, Bridgeport, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yale New Haven Health Bridgeport Hospital, Bridgeport, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Pudimat","sequence":"additional","affiliation":[{"name":"University of Bridgeport, Bridgeport, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Nasrollahizadeh","sequence":"additional","affiliation":[{"name":"Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaveh","family":"Hosseini","sequence":"additional","affiliation":[{"name":"Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedeh Fatemeh","family":"Hosseini Jebelli","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Science, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azin","family":"Alizadeh Asl","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Science, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony Loc","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, UC San Diego Health Moores Cancer Center, San Diego, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260811","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/ejh.14074","article-title":"Chimeric antigen receptor T-cell therapy in hematologic malignancies: successes, challenges, and opportunities.","volume":"112","author":"Ho","year":"2024","journal-title":"Eur J Haematol"},{"key":"R2-20260811","doi-asserted-by":"crossref","first-page":"927153","DOI":"10.3389\/fimmu.2022.927153","article-title":"CAR-T cell therapy in hematological malignancies: current opportunities and challenges.","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"R3-20260811","doi-asserted-by":"crossref","first-page":"925985","DOI":"10.3389\/fimmu.2022.925985","article-title":"CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments.","volume":"13","author":"Jogalekar","year":"2022","journal-title":"Front Immunol"},{"key":"R4-20260811","doi-asserted-by":"crossref","first-page":"7844","DOI":"10.1002\/cam4.5551","article-title":"Chimeric antigen receptor T (CAR-T) cells: novel cell therapy for hematological malignancies.","volume":"12","author":"Abbasi","year":"2023","journal-title":"Cancer Med"},{"key":"R5-20260811","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","article-title":"CAR-T cell therapy: the efficacy and toxicity balance.","volume":"18","author":"Chohan","year":"2023","journal-title":"Curr Hematol Malig Rep"},{"key":"R6-20260811","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jaccao.2020.04.012","article-title":"Cardiovascular effects of CAR T cell therapy: a retrospective study.","volume":"2","author":"Lefebvre","year":"2020","journal-title":"JACC CardioOncol"},{"key":"R7-20260811","doi-asserted-by":"crossref","first-page":"1090103","DOI":"10.3389\/fcvm.2023.1090103","article-title":"Chimeric antigen receptor-T cell therapy-related cardiotoxicity in adults and children cancer patients: a clinical appraisal.","volume":"10","author":"Camilli","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"R8-20260811","doi-asserted-by":"crossref","first-page":"932347","DOI":"10.3389\/fcvm.2022.932347","article-title":"Cardiovascular disease and chimeric antigen receptor cellular therapy.","volume":"9","author":"Rao","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"R9-20260811","first-page":"1","article-title":"Bibliometric method for mapping the state-of-the-art and identifying research gaps and trends in literature: an essential instrument to support the development of scientific projects.","volume":"85856","author":"Oliveira","year":"2019","journal-title":"Scientometrics Recent Adv"},{"key":"R10-20260811","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/asi.21181","article-title":"Bibliometrics and citation analysis: from the science citation index to cybermetrics.","volume":"61","author":"Nicolaisen","year":"2010","journal-title":"J Am Soc Inf Sci Technol"},{"key":"R11-20260811","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1097\/MS9.0000000000003089","article-title":"Global research trends on DPP-4 inhibitors and cardiovascular outcomes: a comprehensive bibliometric analysis.","volume":"87","author":"Amini-Salehi","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"key":"R12-20260811","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1097\/MS9.0000000000003080","article-title":"Bibliometric analysis of artificial intelligence applications in cardiovascular imaging: trends, impact, and emerging research areas.","volume":"87","author":"Alotaibi","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"key":"R13-20260811","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1097\/MS9.0000000000003112","article-title":"Artificial intelligence in cardiovascular procedures: a bibliometric and visual analysis study.","volume":"87","author":"Gadhachanda","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"key":"R14-20260811","doi-asserted-by":"crossref","first-page":"1025861","DOI":"10.3389\/fimmu.2022.1025861","article-title":"Bibliometric and visual analysis of neutrophil extracellular traps from 2004 to 2022.","volume":"13","author":"Wan","year":"2022","journal-title":"Front Immunol"},{"key":"R15-20260811","doi-asserted-by":"crossref","first-page":"101332","DOI":"10.1016\/j.cpcardiol.2022.101332","article-title":"Global research trends on ventricular remodeling: a bibliometric analysis from 2012 to 2022.","volume":"47","author":"Meng","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"R16-20260811","doi-asserted-by":"crossref","first-page":"105565","DOI":"10.1016\/j.compbiomed.2022.105565","article-title":"A bibliometric analysis of diffuse large B-cell lymphoma research from 2001 to 2020.","volume":"146","author":"Jiang","year":"2022","journal-title":"Comput Biol Med"},{"key":"R17-20260811","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1097\/MS9.0000000000003034","article-title":"Exploring the evolution of evidence synthesis: a bibliometric analysis of umbrella reviews in medicine.","volume":"87","author":"Nayak","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"key":"R18-20260811","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1097\/MS9.0000000000003019","article-title":"Triglyceride-glucose index as a marker in cardiovascular diseases: a bibliometric study and visual analysis.","volume":"87","author":"Alotaibi","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"key":"R19-20260811","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/asi.20317","article-title":"CiteSpace II: Detecting and visualizing emerging trends and transient patterns in scientific literature.","volume":"57","author":"Chen","year":"2006","journal-title":"J Am Soc Inf Sci Technol"},{"key":"R20-20260811","doi-asserted-by":"crossref","first-page":"734514","DOI":"10.3389\/fcvm.2021.734514","article-title":"A bibliometric analysis of exosomes in cardiovascular diseases from 2001 to 2021.","volume":"8","author":"Ma","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"R21-20260811","first-page":"724","article-title":"CiteSpace II: visualization and knowledge discovery in bibliographic databases.","volume":"2005","author":"Synnestvedt","year":"2005","journal-title":"AMIA Annu Symp Proc"},{"key":"R22-20260811","doi-asserted-by":"crossref","first-page":"6602","DOI":"10.1097\/MS9.0000000000002592","article-title":"Glucagon-like peptide-1 agonists in cardiovascular diseases: a bibliometric analysis from inception to 2023.","volume":"86","author":"Mahapatro","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"key":"R23-20260811","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic malignancies.","volume":"123","author":"Maus","year":"2014","journal-title":"Blood"},{"key":"R24-20260811","doi-asserted-by":"crossref","first-page":"33961","DOI":"10.18632\/oncotarget.5582","article-title":"Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"R25-20260811","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cell.2015.03.045","article-title":"Immunotherapy: the path to win the war on cancer?","volume":"161","author":"Topalian","year":"2015","journal-title":"Cell"},{"key":"R26-20260811","doi-asserted-by":"crossref","first-page":"44179","DOI":"10.18632\/oncotarget.6175","article-title":"Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy.","volume":"6","author":"Tang","year":"2015","journal-title":"Oncotarget"},{"key":"R27-20260811","doi-asserted-by":"crossref","first-page":"115015","DOI":"10.1016\/j.biopha.2023.115015","article-title":"Evaluation of the association of chronic inflammation and cancer: Insights and implications.","volume":"164","author":"Nigam","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"R28-20260811","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/978-3-030-63761-3_17","article-title":"How prevalent is cancer in confirmed cases with coronaviruses and severe acute respiratory syndromes?","volume":"1318","author":"Fotouhi","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"R29-20260811","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.bbmt.2020.04.008","article-title":"Chimeric antigen receptor T cell therapy during the COVID-19 pandemic.","volume":"26","author":"Bachanova","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"R30-20260811","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jaccao.2020.02.011","article-title":"CAR T cell therapy-related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity?","volume":"2","author":"Ghosh","year":"2020","journal-title":"JACC CardioOncol"},{"key":"R31-20260811","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy \u2013 assessment and management of toxicities.","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R32-20260811","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1136\/heartjnl-2020-318083","article-title":"Cardiotoxicities of novel cancer immunotherapies.","volume":"107","author":"Stein-Merlob","year":"2021","journal-title":"Heart"},{"key":"R33-20260811","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/ejhf.1292","article-title":"Activity and outcomes of a cardio-oncology service in the United Kingdom\u2014a five-year experience.","volume":"20","author":"Pareek","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"R34-20260811","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.120.048100","article-title":"Chimeric antigen receptor T-cell therapy-associated cardiomyopathy in patients with refractory or relapsed non-hodgkin lymphoma.","volume":"142","author":"Ganatra","year":"2020","journal-title":"Circulation"},{"key":"R35-20260811","doi-asserted-by":"crossref","first-page":"e001159","DOI":"10.1136\/jitc-2020-001159","article-title":"Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies.","volume":"8","author":"Shalabi","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"R36-20260811","doi-asserted-by":"crossref","first-page":"924208","DOI":"10.3389\/fonc.2022.924208","article-title":"Cardiovascular effects associated with chimeric antigen receptor T cell therapy in cancer patients: a meta-analysis.","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"key":"R37-20260811","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3390\/cancers15030663","article-title":"CAR-T: what is next?.","volume":"15","author":"Chen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R38-20260811","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jcyt.2019.12.004","article-title":"The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.","volume":"22","author":"Braendstrup","year":"2020","journal-title":"Cytotherapy"},{"key":"R39-20260811","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11912-021-01068-0","article-title":"Cardiovascular toxicities of CAR T-cell therapy.","volume":"23","author":"Patel","year":"2021","journal-title":"Curr Oncol Rep"},{"issue":"16_suppl","key":"R40-20260811","doi-asserted-by":"crossref","first-page":"e14534","DOI":"10.1200\/JCO.2024.42.16_suppl.e14534","article-title":"Risk stratification for immune effector cell-associated neurotoxicity syndrome in patients receiving chimeric antigen receptor T cell therapy.","volume":"42","author":"Chishinga","year":"2024","journal-title":"J Clin Oncol"},{"key":"R41-20260811","doi-asserted-by":"crossref","first-page":"102504","DOI":"10.1016\/j.eclinm.2024.102504","article-title":"Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort study.","volume":"69","author":"Korell","year":"2024","journal-title":"eClinicalMedicine"},{"key":"R42-20260811","doi-asserted-by":"crossref","first-page":"25151355241305856","DOI":"10.1177\/25151355241305856","article-title":"Artificial intelligence for chimeric antigen receptor-based therapies: a comprehensive review of current applications and future perspectives.","volume":"12","author":"Shahzadi","year":"2024","journal-title":"Ther Adv Vaccines Immunother"},{"key":"R43-20260811","doi-asserted-by":"crossref","first-page":"621","DOI":"10.4070\/kcj.2022.0353","article-title":"Efficiency of MVP ECG risk score for prediction of long-term atrial fibrillation in patients with ICD for heart failure with reduced ejection fraction.","volume":"53","author":"Pay","year":"2023","journal-title":"Korean Circ J"},{"key":"R44-20260811","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00059-020-04972-6","article-title":"A simple formula to predict echocardiographic diastolic dysfunction\u2014electrocardiographic diastolic index.","volume":"46","author":"Hayiro\u011flu","year":"2021","journal-title":"Herz"},{"key":"R45-20260811","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4274\/balkanmedj.galenos.2023.06042023","article-title":"The role of artificial intelligence in coronary artery disease and atrial fibrillation.","volume":"40","author":"Hayiro\u011flu","year":"2023","journal-title":"Balkan Med J"},{"key":"R46-20260811","doi-asserted-by":"crossref","first-page":"e011504","DOI":"10.1161\/CIRCOUTCOMES.124.011504","article-title":"Artificial intelligence\u2013enhanced risk stratification of cancer therapeutics\u2013related cardiac dysfunction using electrocardiographic images.","volume":"18","author":"Oikonomou","year":"2025","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R47-20260811","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3390\/cancers15041003","article-title":"Systematic review on CAR-T cell clinical trials up to 2022: Academic Center Input.","volume":"15","author":"Wang","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R48-20260811","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41423-020-00555-x","article-title":"Clinical development of CAR T cell therapy in China: 2020 update.","volume":"18","author":"Wei","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"R49-20260811","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1002\/ijc.33156","article-title":"Cost of decentralized CAR T-cell production in an academic nonprofit setting.","volume":"147","author":"Ran","year":"2020","journal-title":"Int J Cancer"},{"key":"R50-20260811","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/bjh.16685","article-title":"Upsetting the apple CAR-T (chimeric antigen receptor T-cell therapy) \u2013 sustainability mandates USA innovation.","volume":"190","author":"Pantin","year":"2020","journal-title":"Br J Haematol"},{"issue":"13 Suppl","key":"R51-20260811","first-page":"S253","article-title":"Improving outcomes and mitigating costs associated with CAR T-cell therapy.","volume":"27","author":"Borgert","year":"2021","journal-title":"Am J Manag Care"},{"key":"R52-20260811","doi-asserted-by":"crossref","first-page":"687822","DOI":"10.3389\/fimmu.2021.687822","article-title":"Obstacles and coping strategies of CAR-T cell immunotherapy in solid tumors.","volume":"12","author":"Miao","year":"2021","journal-title":"Front Immunol"},{"key":"R53-20260811","first-page":"119","article-title":"CAR T-Cell therapy for patients with multiple myeloma: current evidence and challenges.","volume":"12","author":"Rendo","year":"2022","journal-title":"Blood Lymphat Cancer"},{"key":"R54-20260811","doi-asserted-by":"crossref","first-page":"e691","DOI":"10.1097\/HS9.0000000000000691","article-title":"Anti-BCMA CAR T-cell therapy: changing the natural history of multiple myeloma.","volume":"6","author":"Puertas","year":"2022","journal-title":"Hemasphere"},{"key":"R55-20260811","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future.","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"R56-20260811","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study.","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"R57-20260811","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma.","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"R58-20260811","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.medj.2024.03.001","article-title":"CAR-T therapy and targeted treatments: emerging combination strategies in solid tumors.","volume":"5","author":"Liu","year":"2024","journal-title":"Med"},{"key":"R59-20260811","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s12935-022-02778-6","article-title":"CAR-T cell combination therapy: the next revolution in cancer treatment.","volume":"22","author":"Al-Haideri","year":"2022","journal-title":"Cancer Cell Int"},{"key":"R60-20260811","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3892\/ol.2023.13867","article-title":"Combination of CAR\u2011T cell therapy and radiotherapy: opportunities and challenges in solid tumors (Review).","volume":"26","author":"Zhong","year":"2023","journal-title":"Oncol Lett"},{"key":"R61-20260811","doi-asserted-by":"crossref","first-page":"1368732","DOI":"10.3389\/fonc.2024.1368732","article-title":"Prospects and challenges of CAR-T cell therapy combined with ICIs.","volume":"14","author":"Lv","year":"2024","journal-title":"Front Oncol"},{"key":"R62-20260811","doi-asserted-by":"crossref","first-page":"1140541","DOI":"10.3389\/fimmu.2023.1140541","article-title":"Combining chemotherapy with CAR-T cell therapy in treating solid tumors.","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"R63-20260811","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12410-023-09584-2","article-title":"Cardiovascular magnetic resonance assessment of immunotherapy cardiotoxicity.","volume":"16","author":"Voigt","year":"2023","journal-title":"Curr Cardiovasc Imaging Rep"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000042314","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T08:01:21Z","timestamp":1786435281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000042314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":63,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042314","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]}}}